- Home
- RGP vs IMMP Comparison
RGP vs IMMP Comparison
Compare RGP & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGP
- IMMP
- Stock Information
- Founded
- RGP 1996
- IMMP 1987
- Country
- RGP United States
- IMMP Australia
- Employees
- RGP N/A
- IMMP N/A
- Industry
- RGP Business Services
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- RGP Consumer Discretionary
- IMMP Health Care
- Exchange
- RGP Nasdaq
- IMMP Nasdaq
- Market Cap
- RGP 303.9M
- IMMP 304.0M
- IPO Year
- RGP 2006
- IMMP N/A
- Fundamental
- Price
- RGP $8.69
- IMMP $1.91
- Analyst Decision
- RGP Hold
- IMMP Buy
- Analyst Count
- RGP 3
- IMMP 2
- Target Price
- RGP $13.00
- IMMP $8.50
- AVG Volume (30 Days)
- RGP 453.8K
- IMMP 95.6K
- Earning Date
- RGP 01-02-2025
- IMMP 02-27-2025
- Dividend Yield
- RGP 6.56%
- IMMP N/A
- EPS Growth
- RGP N/A
- IMMP N/A
- EPS
- RGP N/A
- IMMP N/A
- Revenue
- RGP $582,058,000.00
- IMMP $2,563,302.00
- Revenue This Year
- RGP N/A
- IMMP N/A
- Revenue Next Year
- RGP $16.91
- IMMP $47.79
- P/E Ratio
- RGP N/A
- IMMP N/A
- Revenue Growth
- RGP N/A
- IMMP 9.59
- 52 Week Low
- RGP $7.90
- IMMP $1.66
- 52 Week High
- RGP $14.29
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- RGP 55.05
- IMMP 40.99
- Support Level
- RGP $8.31
- IMMP $2.00
- Resistance Level
- RGP $8.90
- IMMP $2.05
- Average True Range (ATR)
- RGP 0.38
- IMMP 0.09
- MACD
- RGP 0.00
- IMMP -0.02
- Stochastic Oscillator
- RGP 29.05
- IMMP 2.78
About RGP Resources Connection Inc.
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.